Skip to main content
AAN.com
Article
August 19, 2019

A prospective comparative study and analysis of predictors of SUNA and SUNCT

September 17, 2019 issue
93 (12) e1127-e1137

Abstract

Objective

Despite the similar phenotypes, comparison between short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with autonomic features (SUNA) has hitherto not been possible due to the dearth of studies validating the phenotype of SUNA. Therefore, these 2 syndromes have been kept separate in the International Classification of Headache Disorders. The aim of this study is to characterize and compare the clinical phenotypes of large clinic-based cohorts of patients with SUNA and SUNCT.

Methods

The clinical phenotype of consecutive patients with SUNA identified from a single specialist headache center in the United Kingdom between 2007 and 2012 was studied and compared to that of patients with SUNCT.

Results

Sixty-three patients with SUNA (18 male, 28.6%) and 70 patients with SUNCT (32 male, 35.7%) were included. The demographic and clinical characteristics of patients with SUNA were similar to those of patients with SUNCT. Ptosis and rhinorrhea were predictors of SUNCT. The corresponding odds ratios (ORs) (95% confidence interval) were 3.79 (1.64–8.77, p = 0.002) and 2.46 (1.09–5.59, p = 0.031), respectively. The presence of spontaneous only attacks was a predictor for SUNA (OR 2.58 [1.10–6.05], p = 0.029).

Conclusion

No major clinical differences have emerged between SUNCT and SUNA, bar the fact that SUNCT is characterized by more prominent cranial autonomic features and triggerability. We propose that the 2 disorders be placed together in a single diagnostic category for which new diagnostic criteria are proposed.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders 3rd edition. Cephalalgia 2018;38:1–211.
2.
Pareja JA, Sjaastad O. SUNCT syndrome: a clinical review. Headache 1997;37:195–202.
3.
Matharu MS, Cohen AS, Boes CJ, Goadsby PJ. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome: a review. Curr Pain Headache Rep 2003;7:308–318.
4.
Cohen AS, Matharu MS, Goadsby PJ. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) or cranial autonomic features (SUNA): a prospective clinical study of SUNCT and SUNA. Brain 2006;129:2746–2760.
5.
Williams MH, Broadley SA. SUNCT and SUNA: clinical features and medical treatment. J Clin Neurosci 2008;15:526–534.
6.
Weng H-Y, Cohen AS, Schankin C, Goadsby PJ. Phenotypic and treatment outcome data on SUNCT and SUNA, including a randomised placebo-controlled trial. Cephalalgia 2017;38:1554–1563.
7.
Lambru G, Nesbitt A, Shanahan P, Matharu MS. Coexistence of hemiplegic migraine with SUNCT or SUNA: a case series. Cephalalgia 2012;32:258–262.
8.
Chitsantikul P, Becker WJ. SUNCT, SUNA and pituitary tumors: clinical characteristics and treatment. Cephalalgia 2013;33:160–170.
9.
Pareja JA, Barón M, Gili P, et al. Objective assessment of autonomic signs during triggered first division trigeminal neuralgia. Cephalalgia 2002;22:251–255.
10.
Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua: parenteral indomethacin: the “indotest”. Headache 1998;38:122–128.
11.
Cohen AS. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing. Cephalalgia 2007;27:824–832.
12.
Pareja JA, Sjaastad O. SUNCT syndrome in the female. Headache 1994;34:217–220.
13.
Manzoni GC. Gender ratio of cluster headache over the years: a possible role of changes in lifestyle. Cephalalgia 1998;18:138–142.
14.
Lambru G, Matharu MS. Trigeminal autonomic cephalalgias: a review of recent diagnostic, therapeutic and pathophysiological developments. Ann Indian Acad Neurol 2012;15(suppl 1):S51–S61.
15.
Cademartiri C, Torelli P, Cologno D, Manzoni GC. Upper and lower cluster headache: clinical and pathogenetic observations in 608 patients. Headache 2002;42:630–637.
16.
Cittadini E, Goadsby PJ. Hemicrania continua: a clinical study of 39 patients with diagnostic implications. Brain 2010;133:1973–1986.
17.
Cittadini E, Matharu MS, Goadsby PJ. Paroxysmal hemicrania: a prospective clinical study of 31 cases. Brain 2008;131:1142–1155.
18.
Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders 2nd edition. Cephalalgia 2004;24(suppl 1):1–195.
19.
Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders 3rd edition (beta version). Cephalalgia 2013;33:629–808.
20.
Drummond PD. Autonomic disturbances in cluster headache. Brain 1988;111(pt 5):1199–1209.
21.
Paliwal VK, Singh P, Kumar A, Rahi SK, Gupta RK. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) with preserved refractory period: report of three cases. J Headache Pain 2012;13:167–169.
22.
Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic implications. Neurology 2002;58:354–361.
23.
Obermann M, Yoon MS, Ese D, et al. Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia. Neurology 2007;69:835–841.
24.
Schulte L, May A. What makes migraine a migraine: of the importance of disease classifications in scientific research. Cephalalgia 2015;35:1337–1338.
25.
Sjaastad O, Saunte C, Salvesen R, et al. Shortlasting unilateral neuralgiform headache attacks with conjunctival injection, tearing, sweating, and rhinorrhea. Cephalalgia 1989;9:147–156.

Information & Authors

Information

Published In

Neurology®
Volume 93Number 12September 17, 2019
Pages: e1127-e1137
PubMed: 31427501

Publication History

Received: January 9, 2019
Accepted: May 29, 2019
Published online: August 19, 2019
Published in issue: September 17, 2019

Permissions

Request permissions for this article.

Disclosure

G. Lambru has received speaker honoraria, funding for travel, and honoraria for participation in advisory boards sponsored by Allergan and Novartis. He has received speaker honoraria and funding for travel from electroCore, Nevro Corp, and Autonomic Technologies. K. Rantell and A. Levy report no disclosures relevant to the manuscript. M. Matharu serves on the advisory board for Allergan, St. Jude Medical, and Medtronic and has received payment for the development of educational presentations from Allergan, Merck Sharpe and Dohme Ltd, Medtronic, and electroCore. Go to Neurology.org/N for full disclosures.

Study Funding

No targeted funding reported.

Authors

Affiliations & Disclosures

Giorgio Lambru, MD
From the Headache Group (G.L., A.L., M.S.N.) and Education Unit (K.R.), UCL Queen Square Institute of Neurology; and National Hospital for Neurology and Neurosurgery (G.L., A.L., M.S.N.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
(1) Allergan: personal compensation for serving at their scientific advisory board (2)Novartis: personal compensation for serving at their scientific advisory board
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Allergan: Funding for travel and speaker honoraria (2) Novartis: Funding for travel and speaker honoraria (3) ElectroCore: Funding for travel and speaker honoraria (4): Nevro: Funding for travel and speaker honoraria (5) Autonomic Technologies: Funding for travel and speaker honoraria
Editorial Boards:
1.
(1) Advisory board member of the Journal of Headache and Pain
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Khadija Rantell, PhD
From the Headache Group (G.L., A.L., M.S.N.) and Education Unit (K.R.), UCL Queen Square Institute of Neurology; and National Hospital for Neurology and Neurosurgery (G.L., A.L., M.S.N.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Andrew Levy, MD
From the Headache Group (G.L., A.L., M.S.N.) and Education Unit (K.R.), UCL Queen Square Institute of Neurology; and National Hospital for Neurology and Neurosurgery (G.L., A.L., M.S.N.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Manjit S. Matharu, MBChB, FRCP, PhD
From the Headache Group (G.L., A.L., M.S.N.) and Education Unit (K.R.), UCL Queen Square Institute of Neurology; and National Hospital for Neurology and Neurosurgery (G.L., A.L., M.S.N.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
(1) Autonomic Technologies Inc (2) Allergan (3) Medtronic (4) Novartis (5) TEVA (6) Eli Lilly
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Allergan, speaker honoraria (2) Novartis, speaker honoraria (3) TEVA, speaker honoraria
Editorial Boards:
1.
(1) Headache Currents, subeditor, 9 years, (2)Frontiers in Headache Medicine, Member of editorial board, 1 year (3)BMC Neurology, Member of editorial board, 2 year (4) Australian and New Zealand Journal of Psychiatry, Member of editorial board, 5 year (5) Journal of Headache and Pain, Member of editorial board, 5 year
Patents:
1.
(1) Medical App for Headache Diagnosis and Monitoring
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Autonomic Technologies Inc (2) Allergan (3) Medtronic (4) Novartis (5) TEVA (6) Eli Lilly
Speakers' Bureaus:
1.
(1) Allergan (2) Novartis (3) TEVA
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Autonomic Technologies Inc (2) Allergan (3) Medtronic (4) electroCore (5) Abbott
Research Support, Government Entities:
1.
National Institute of Health Research, RP-PG -1212-200018, collaborator, 5 years
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Matharu [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Pearls & Oy-sters: Late-Onset Presumed SUNA in a 91-Year-Old Woman With Headache, Neurology, 104, 9, (2025)./doi/10.1212/WNL.0000000000213626
    Abstract
  2. SUNCT and SUNA, Distinct Disorders or Spectrum of a Single Clinical Entity? A Meta-analysis, Neurological Sciences and Neurophysiology, 41, 4, (193-202), (2025).https://doi.org/10.4103/nsn.nsn_122_24
    Crossref
  3. Primary headaches are a continuum driven by a common process, Discover Medicine, 1, 1, (2024).https://doi.org/10.1007/s44337-024-00068-w
    Crossref
  4. Epidemiology and clinical features of short-lasting unilateral neuralgiform headache attacks: A systematic review and meta-analysis, Cephalalgia, 44, 8, (2024).https://doi.org/10.1177/03331024241271976
    Crossref
  5. An update on pharmacotherapy for trigeminal neuralgia, Expert Review of Neurotherapeutics, 24, 8, (773-786), (2024).https://doi.org/10.1080/14737175.2024.2365946
    Crossref
  6. Lacrimal Neuralgia: A Case Report and Comprehensive Review of the Literature, Current Pain and Headache Reports, 28, 9, (929-939), (2024).https://doi.org/10.1007/s11916-024-01250-6
    Crossref
  7. SUNCT, SUNA and short-lasting unilateral neuralgiform headache attacks: Debates and an update, Cephalalgia, 44, 2, (2024).https://doi.org/10.1177/03331024241232256
    Crossref
  8. A Retrospective Comparative Study in Patients with SUNA and SUNCT, Annals of Indian Academy of Neurology, 26, 5, (672-677), (2023).https://doi.org/10.4103/aian.aian_502_23
    Crossref
  9. Approaching headaches and facial pains in eye care practice, International Ophthalmology, 43, 9, (3433-3444), (2023).https://doi.org/10.1007/s10792-023-02741-y
    Crossref
  10. Recent Advances and Updates in Trigeminal Autonomic Cephalalgias, Seminars in Neurology, 42, 04, (474-478), (2022).https://doi.org/10.1055/s-0042-1758043
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Short Form

Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share